Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670667 · ClinicalTrials.gov registry record
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,132
- Enrollment target
NCT03670667 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,132 participants.
The verdict
NCT03670667 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,132 participants
- Enrollment target
Study Summary
An observational study to determine the risk of cancer associated with the use of abatacept and other biologic agents among rheumatoid arthritis patients
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,132 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2019-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670667
The ClinicalTrials.gov registry entry for NCT03670667 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03670667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03670667 about?
NCT03670667 is a clinical study titled "A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents". An observational study to determine the risk of cancer associated with the use of abatacept and other biologic agents among rheumatoid arthritis patients
What is the current status of trial NCT03670667?
This trial is currently completed. The enrollment target is 1,132 participants. The study started on 2017-02-22. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03670667?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03670667?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.